



# International Journal of Pharmacy and Natural Medicines

Journal Home Page: [www.pharmaresearchlibrary.com/ijpnm](http://www.pharmaresearchlibrary.com/ijpnm)



## RESEARCH ARTICLE

### Development and Validation of RP-HPLC Method for Simultaneous Estimation of Emtricitabine and Lamivudine in Pharmaceutical Dosage Form

V. Swathi<sup>1</sup>, Dr. D. Naresh<sup>2</sup>, Dr. Gampa Vijay Kumar<sup>3\*</sup>

<sup>1</sup>KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy, Telangana, India.

<sup>2</sup>KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy, Telangana, India.

<sup>3</sup>Professor and Head, Dept. of Pharmacy, KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy, Telangana, India.

#### ABSTRACT

A new method was established for simultaneous estimation of a Emtricitabine and Lamivudine by RP-HPLC method. The chromatographic conditions were successfully developed for the separation of Emtricitabine and Lamivudine by using ZODIAC –SIL RP C18 4.6×100 mm 3.0µm column, flow rate was 1.0 ml/min, mobile phase ratio was (75:25 v/v) acetonitrile : phosphate buffer (KH<sub>2</sub>PO<sub>4</sub> and K<sub>2</sub>HPO<sub>4</sub>) pH 2.5 (pH was adjusted with orthophosphoric acid), detection wave length was 292 nm. The instrument used was Shimadzu, UV detector, LC solutions. The retention times were found to be 2.746 mins and 3.668 mins. The % purity of Emtricitabine and Lamivudine was found to be 99.95% and 100.63% respectively. The system suitability parameters for Emtricitabine and Lamivudine such as theoretical plates and tailing factor were found to be 3923, 1.43 and 3348 and 1.46, the resolution was found to be 8.67. The analytical method was validated according to ICH guidelines (ICH, Q2 (R1)). The linearity study for Emtricitabine and Lamivudine was found in concentration range of 5µg/mL-25µg/mL and 5µg/mL-25µg/mL and correlation coefficient (r<sup>2</sup>) was found to be 0.999 and 0.999, % recovery was found to be 99.56% and 99.48%, %RSD for repeatability was 1.67 and 1.48, % RSD for intermediate precision was 1.83 and 1.05 respectively. The precision study was precise, robust, and repeatable. LOD value was 0.110 and 3.0, and LOQ value was 0.33 and 9.09 respectively.

**Key words:** Emtricitabine, Lamivudine, RP-HPLC, Acetonitrile.

#### ARTICLE INFO

##### \*Corresponding Author

Dr. Gampa Vijay Kumar  
KGR Institute of Technology and Management, Rampally, Kesara, Rangareddy, Telangana, India.  
MS-ID: IJPNM4071



PAPER QR-CODE

**ARTICLE HISTORY:** Received 01 May 2019, Accepted 29 June 2019, Available Online 15 December 2019

**Copyright**© 2019 Dr. Gampa Vijay Kumar, et al. Production and hosting by Pharma Research Library. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.


**Citation:** Gampa Vijay Kumar, et al. Development and Validation of RP-HPLC Method for Simultaneous Estimation of Emtricitabine and Lamivudine in Pharmaceutical Dosage Form. *Int. J. Pharm. Natural Med.*, 2019, 7(2): 57-61.

#### CONTENTS

1. Introduction . . . . .	58
2. Materials and Method. . . . .	58
3. Results and Discussion . . . . .	58
4. Conclusion. . . . .	61
5. References. . . . .	61
International Journal of Pharmacy and Natural Medicines	57


## 1. Introduction

Emtricitabine (commonly called FTC, systematic name 2',3'-dideoxy-5-fluoro-3'-thiacytidine), with trade name Emtriva (formerly Coviracil), is a nucleoside reverse-transcriptase inhibitor (NRTI) for the prevention and treatment of HIV infection in adults and children.



**Fig 1:** Structure of Emtricitabine

Lamivudine, commonly called 3TC, is an antiretroviral medication used to prevent and treat HIV/AIDS. It is also used to treat chronic hepatitis B when other options are not possible. It is effective against both HIV-1 and HIV-2. It is typically used in combination with other antiretrovirals such as zidovudine and abacavir. Lamivudine may be included as part of post-exposure prevention in those who have been potentially exposed to HIV.



**Fig 2:** Structure of Lamivudine

## 2. Materials and Methods

### Instrumentation:

System Shimadzu, Pump Analytical HPLC isocratic pump, Detector UV detector, Software LC solutions software, ZODIAC –SIL RP C18 4.6×100 mm 3.0µm column, Sonicator SE60US, U.V double beam spectrophotometer T60, UV win 5 pH meter AD 102U, Weighing machine ER 200A Ascotet.

### Chemicals:

Emtricitabine and Lamivudine,  $\text{KH}_2\text{PO}_4$ , Water and Methanol for HPLC, Acetonitrile for HPLC, Ortho phosphoric Acid,  $\text{K}_2\text{HPO}_4$ .

### Optimized chromatographic conditions

Column : Zodiac sil RP C18 4.6×100mm 3.0µm  
Mobile phase ratio : ACN: pH 2.5 buffer (75: 25 % v/v)

Detection wavelength: 292nm

Flow rate : 1.0 ml/min


Injection volume : 20µl

Column temperature : Ambient

Auto sampler temperature: Ambient

Run time : 8 min

Retention time : 2.764 and 3.668 mins.



**Fig 3:** Chromatogram from optimized conditions

**Observation:** The retention time of both peaks was good response and height of peaks was good.

### Sample solution preparation:

20.02 mg of Emtricitabine and 30.02mg of Lamivudine tablet powder were accurately weighed and transferred into a 10 ml clean dry volumetric flask, add about 7 ml of diluent and sonicate to dissolve it completely and making volume up to the mark with the same solvent (Stock solution). Further pipette 1.5 ml of the above stock solution into a 10 ml volumetric flask and was diluted up to the mark with diluents.

### Standard solution preparation:

10 mg of Emtricitabine and 10 mg of Lamivudine working standard was accurately weighed and transferred into a 10 ml clean dry volumetric flask and add about 7 ml of diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent (Stock solution). Further pipette out 1.5 ml of the above stock solution into a 10 ml volumetric flask and was diluted up to the mark with diluent.

### Method Validation

- ✓ System Suitability
- ✓ Linearity
- ✓ Specificity
- ✓ Precision ( Repeatability & Intermediate precision)
- ✓ Accuracy
- ✓ Limit of Detection and Limit of Quantification
- ✓ Robustness

## 3. Results and Discussion

**Table 1:** Results for system suitability

S.No	Peak Name	$R_t$	Area	Height	USP plate count
1	Emtricitabine	2.746	10966728	1412054	3445
2	Lamivudine	3.668	1397231	177886	5441



**Table 2:** Linearity results for Emtricitabine

S.No	Linearity Level	Concentration	Area
1	I	5 ppm	221543

2	II	10 ppm	426277
3	III	15 ppm	624999
4	IV	20 ppm	826124
5	V	25 ppm	1022139
Correlation Coefficient			0.999

**Table 3:** Linearity results for Lamivudine

S.No	Linearity Level	Concentration	Area
1	I	5 ppm	211543
2	II	10 ppm	426277
3	III	15 ppm	634999
4	IV	20 ppm	846124
5	V	25 ppm	1042139
Correlation Coefficient			0.999

**Fig 4:** Calibration curve of Emtricitabine**Fig 5:** Calibration curve of Lamivudine**Table 4:** Showing accuracy results for Emtricitabine

%Concentration (at specification level)	Average area	Amount added (mg)	Amount found (mg)	% Recovery	Mean recovery
50%	7371253	5	4.9	99.91%	99.56%
100%	14634226.7	10	9.98	99.18%	
150%	2243270.7	15	14.89	99.60%	

**Table 5:** Showing accuracy results for Lamivudine

%Concentration (at specification level)	Average area	Amount added (mg)	Amount found (mg)	% Recovery	Mean recovery
50%	484733	5.0	4.9	99.53%	99.48%
100%	967998	10.0	9.59	99.38%	
150%	145437	15.0	14.85	99.52%	

**Table 6:** Showing % RSD results for Emtricitabine

	Name	RT	Area	Height(v)
1	Emtricitabine	2.729	115191	17639
2	Emtricitabine	2.723	110395	16008
3	Emtricitabine	2.728	113883	16394
4	Emtricitabine	2.728	111611	16507
5	Emtricitabine	2.726	112693	16386
Mean			112693	
Std.Dev.			1884.2	
%RSD			1.67	

**Table 7:** Showing %RSD results for Lamivudine

	Name	RT	Area	Height(v)
1	Lamivudine	3.665	2929297	280493
2	Lamivudine	3.667	2871804	245324
3	Lamivudine	3.670	2981706	253065
4	Lamivudine	3.668	2883219	248703
5	Lamivudine	3.665	2920005	258365
Mean			2917206	
Std.Dev.			43389.9	
%RSD			1.48	

**Table 9:** Showing intermediate precision results for Emtricitabine

	Name	RT	Area	Height(v)
1	Emtricitabine	2.729	105191	17601
2	Emtricitabine	2.723	100395	16000
3	Emtricitabine	2.728	103883	16286
4	Emtricitabine	2.728	101611	16486
5	Emtricitabine	2.726	102386	16275
Mean			102693	
Std.Dev.			1884.2	
%RSD			1.83	

**Table 10:** Showing intermediate precision injection

	Name	RT	Area	Height(v)
1	Lamivudine	3.665	2829297	280486
2	Lamivudine	3.667	2871804	245316
3	Lamivudine	3.670	2881706	253005
4	Lamivudine	3.668	2883219	248613
5	Lamivudine	3.665	2820008	258215
Mean			2257206	
Std.Dev.			30219.4	
%RSD			1.05	

**Table 11:** Showing results for Limit of Detection

Drug name	Standard deviation( )	Slope(s)	LOD( $\mu$ g)
Emtricitabine	1884	56336	0.110
Lamivudine	43389	47688	3.0

**Table 12:** Showing results for Limit of Quantitation

Drug name	Standard deviation( )	Slope(s)	LOQ( $\mu$ g)
Emtricitabine	1884	56336	0.33
Lamivudine	43389	47688	9.09

**Table 13:** Showing robustness(flow rate) results for Emtricitabine

S. No	Flow rate (ml/min)	System suitability results	
		USP Plate Count	USP Tailing

1	0.8	3696	1.8
<b>2</b>	<b>1.0</b>	<b>3646</b>	<b>1.4</b>
3	1.2	3657	1.8

**Table 14:** Showing robustness(flow rate) results for Lamivudine

S. No	Flow rate (ml/min)	System suitability results	
		USP Plate Count	USP Tailing
1	0.8	3108	1.8
<b>2</b>	<b>1.0</b>	<b>3348</b>	<b>1.4</b>
3	1.2	3057	1.9

**Table 15:** Showing robustness (organic composition) results for Emtricitabine

S. No	Change in organic composition in the mobile phase	System suitability results	
		USP Plate Count	USP Tailing
1	5 % less	3706	1.75
2	<b>*Actual</b>	<b>3646</b>	<b>1.4</b>
3	5 % more	3627	1.8

**Table 16:** Showing robustness (organic composition) results for Lamivudine

S. No	Change in organic composition in the mobile phase	System suitability results	
		USP Plate Count	USP Tailing
1	5 % less	3309	1.86
2	<b>*Actual</b>	<b>3348</b>	<b>1.4</b>
3	5 % more	3220	1.9

#### 4. Conclusion

The RP-HPLC method developed and validated allows a simple and rapid quantitative determination of Emtricitabine and Lamivudine in pharmaceutical dosage forms. All the validation parameters were found to be within the limits according to ICH guidelines.

Simultaneous Estimation of Cefixime And Ofloxacin In A Pharmaceutical Formulation By RP-HPLC Method. Asian Journal of Research in Chemistry and Pharmaceutical Sciences. 2(1), 2014, 1-14.

#### 5. Reference

- [1] Balsano C, Alisi A. Antioxidant effects of natural bioactive compounds. Curr Pharm Des. 2009; 15: 3063–73.
- [2] Anil Dubbaka, Analytical method development and validation for the simultaneous estimation of lamivudine and tenofovir disoproxil fumarate by RP-HPLC method. MOJ Proteomics & Bioinformatics, Volume 4, Issue 5, 2016.
- [3] Anandakumar Karunakaran, A Validated RP - HPLC Method for Simultaneous Estimation of Lamivudine and Tenofovir Disoproxil Fumarate in Pure and in Tablet Dosage Form Indian J Pharm Sci 2/2012 vol. 7
- [4] Dhara S. Bhavsar RP-HPLC method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine, and efavirenz in combined tablet dosage form. Pharm Methods. Indian J Pharm Sci 2012 Jul-Dec; 3(2): 73–78. Vol 6
- [5] R. K. Gummaluri, Simultaneous Method for Determination of Emtricitabine, Tenofovir Disoproxil Fumarate, Elvitegravir and Cobicistat in Tablets By HPLC. Indian J Pharm Sci 2016, 78(4): 532-537.
- [6] CH. Ravikumar , V. Valli Kumari , G. Tuljarani, Method Development And Validation For The